Document is current
Any future updates will be listed below
-
Authors
Brenner, Andrew J. https://orcid.org/0000-0002-3985-253X
Patel, Toral https://orcid.org/0000-0002-8388-8206
Bao, Ande https://orcid.org/0009-0007-0096-2858
Phillips, William T. https://orcid.org/0000-0001-8248-7817
Michalek, Joel E.
Youssef, Michael
Weinberg, Jeffrey S. https://orcid.org/0000-0001-5587-6673
Kamiya Matsuoka, Carlos https://orcid.org/0000-0003-3216-2728
Hedrick, Marc H.
LaFrance, Norman
Moore, Melissa https://orcid.org/0009-0009-2679-7437
Floyd, John R.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA235800, CA054174)
- License Information
-
More Information
Article History
Received: 25 April 2024
Accepted: 18 February 2025
First Online: 7 March 2025
Competing interests
: All authors have reviewed the data analyses, contributed to data interpretation, contributed to the intellectual content of the manuscript, approved the final version to be published, and agree to be accountable for all aspects of the work. A patent for radiolabeled liposomes and their uses (US-20220273832) is assigned to Plus Therapeutics, Inc. and NanoTx, Corp., with M.H., A.J.B., A.B., and W.P. as inventors. A.B., W.P., and J.M., in addition to M.M., N.L.F., and M.H., are consultants and employees of Plus Therapeutics, Inc., respectively. Clinical trial investigation was conducted by A.J.B., T.P., M.Y., and J.S.W. Funding for the clinical trial was provided by the NIH/NCI, CPRIT, and Plus Therapeutics, Inc.
